# ERSTEQ

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ersteq

- Industry: Biotechnology
- Headquarters: Daejeon-City, South Korea
- Total disclosed funding: $0.4M
- Latest round: Seed (Oct 1, 2021)
- Investors on record: 2

## About

Based in Daejeon, South Korea, and founded in 2021, ERSTEQ is a biotechnology firm that conducts joint research with pharmaceutical companies and research institutes to develop new drugs for medical applications by utilizing artificial intelligence technology. In November 2022 ERSTEQ raised a pre-series A funding from Ascendo Ventures and Synergy IB Investment. As of November 2022, Ivoa is the CEO of the company.

The company provides drug ingredient candidate discovery solutions using 3d structural information analysis and biological verification integrated system. ERSTEQ is researching and developing new drugs by continuously collecting data, mutually feeding data on cell, and preclinical animal experiment verification data from company-affiliated research institutes, including pharmacological and physicochemical analysis, and a mapping big data platform between pharmacologically active substances including natural product materials and ingredients.

ERSTEQ plans to use its proceeds from November 2022 funding to fund IND preparation of EST-101, the discovery of metabolic and immuno-oncology drugs, research of newly discovered effective materials, including indications for degenerative brain diseases, and joint research and development with various partners.

## Funding rounds

- Seed, Oct 1, 2021, $0.4M — Korea Tech Incubator for Startup, Mirae Holdings
- Seed, Aug 31, 2021 — Mirae Holdings

## Investors

- Mirae Holdings (https://capitalatlas.ai/funds/mirae-holdings) — Seed
- Korea Tech Incubator for Startup — Seed